The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers by Parato, Kelley A et al.
original article
© The American Society of Gene & Cell Therapy
Molecular Therapy  vol. 20 no. 4, 749–758 apr. 2012  749
Oncolytic  viruses  are  generally  designed  to  be  can-
cer selective on the basis of a single genetic mutation. 
JX-594 is a thymidine kinase (TK) gene-inactivated onco-
lytic vaccinia virus expressing granulocyte-macrophage 
colony-stimulating  factor  (GM-CSF)  and  lac-Z  trans-
genes that is designed to destroy cancer cells through 
replication-dependent cell lysis and stimulation of anti-
tumoral immunity. JX-594 has demonstrated a favorable 
safety profile and reproducible tumor necrosis in a vari-
ety of solid cancer types in clinical trials. However, the 
mechanism(s) responsible for its cancer-selectivity have 
not yet been well described. We analyzed the replication 
of JX-594 in three model systems: primary normal and 
cancer cells, surgical explants, and murine tumor models. 
JX-594 replication, transgene expression, and cytopathic 
effects were highly cancer-selective, and broad spectrum 
activity was demonstrated. JX-594 cancer-selectivity was 
multi-mechanistic; replication was activated by epider-
mal growth factor receptor (EGFR)/Ras pathway signal-
ing, cellular TK levels, and cancer cell resistance to type-I 
interferons (IFNs). These findings confirm a large thera-
peutic index for JX-594 that is driven by common genetic 
abnormalities in human solid tumors. This appears to be 
the first description of multiple selectivity mechanisms, 
both inherent and engineered, for an oncolytic virus. 
These  findings  have  implications  for  oncolytic  viruses 
in general, and suggest that their cancer targeting is a 
complex and multifactorial process.
Received 29 June 2011; accepted 19 November 2011; published online 
20 December 2011. doi:10.1038/mt.2011.276
IntroductIon
Oncolytic  viruses  represent  an  emerging  therapeutic  platform 
for the treatment of human cancer with unique attributes com-
pared with conventional therapeutic modalities.1–4 One especially 
favorable  feature  of  these  therapeutic  agents  is  their  proposed 
selectivity for replication in cancer cells, while sparing normal 
cells and tissues, thus limiting off-target cell killing and toxicities. 
Oncolytic viruses can also be engineered to express therapeutic 
and monitoring transgenes. The expression of these proteins can 
also be highly cancer-selective if controlled by late promoters that 
are turned on after replication is initiated, for example. Since these 
agents can amplify themselves within cancer tissues, and simul-
taneously undergo clearance from normal tissues, they have the 
potential for a very large therapeutic index between cancer and 
normal tissues. This large therapeutic index is in marked contrast 
to the narrow therapeutic index for typical chemotherapeutics. 
The safety of oncolytic viruses in humans has been excellent to 
date, with no reported treatment-related deaths following treat-
ment of over 500 patients.5 Understanding the therapeutic index 
for oncolytic viruses in relevant and representative human tissues, 
and elucidating the selectivity mechanisms involved, is critical for 
the effective design and development of these agents.
The  mechanisms  responsible  for  oncolytic  virus  cancer-
selectivity include both inherent tumor tropism (e.g., vesicular 
stomatitis virus, refs. 6,7 and reovirus, refs. 8,9), and engineered 
selectivity (e.g., adenovirus, refs. 10,11 measles virus, refs. 12,13 
and herpes simplex virus, refs. 14,15) deletion mutants. Poxviruses 
have biological characteristics that make them particularly prom-
ising as oncolytic therapeutics: (i) intravenous stability and effi-
cient delivery to metastatic tumors through the blood, (ii) rapid 
and motile spread within tumors, (iii) large transgene-encoding 
capacity, and (iv) a large safety experience in humans as a vac-
cine.16 The tissue and/or cancer tropism of poxviruses, however, 
is poorly understood. Vaccinia virus binding to cells is mediated 
by the heparan sulfate, a ubiquitous cell surface-associated car-
bohydrate moiety of glycoproteins.17 Cellular uptake is mediated 
through a ubiquitous macropinocytosis mechanism in which the 
virus mimics an apoptotic bleb.18 Therefore, the exquisite selectiv-
ity of specific poxviruses for certain species or tissues is mediated 
within the cytoplasm of infected cells.
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JX-594, the lead product within the oncolytic poxvirus class, 
is an engineered, targeted, and transgene-“armed” oncolytic pox-
virus engineered from the Wyeth vaccine strain (Dryvax; Wyeth 
laboratories, Madison, NJ). JX-594 has an engineered disruption 
of the thymidine kinase (TK) gene for attenuation.19,20 In addition, 
the human CSF2 (granulocyte-macrophage colony-stimulating fac-
tor; GM-CSF) complementary DNA is expressed under the control 
of a synthetic (i.e., engineered) early-late promoter, and the lac-Z 
marker transgene is under control of the p7.5 promoter.19,20 The 
use of this attenuated vaccinia virus in cancer therapy was initially 
proposed purely as a vehicle to express the immunostimulatory 
cytokine GM-CSF, in solid tumors after intratumoral injection as a 
means to induce an anticancer immune response;19 GM-CSF had 
previously been identified as a potent activator of antigen-present-
ing cells in preclinical models.21 Kirn subsequently hypothesized 
that this agent could be used as a replication-selective, systemically 
active, and intravenously administered targeted oncolytic thera-
peutic for cancer.16,22
JX-594 has been well-tolerated in phase 1 and 2 clinical tri-
als to date, both by intratumoral injection19,22 and by intravenous 
administration.23  Virus  replication,  GM-CSF  expression  and 
biological activity, and tumor responses have been reported in a 
diverse spectrum of cancer types; of note, infection and necro-
sis of distant, noninjected tumors have been shown reproducibly. 
While transient flu-like symptoms are common, no significant 
normal tissue toxicity has been reported to date.
Other  oncolytic  vaccinia  viruses  in  preclinical  and  clinical 
development include vvDD (a TK- and vaccinia growth factor-
deleted mutant),24 JX-963 (vvDD expressing GM-CSF; Jennerex, 
San  Francisco,  CA),25  JX-795  (TK-  and  B18R-deletion  mutant 
expressing  IFN-β;  Jennerex,  San  Francisco,  CA),26  VV-FCU1 
(Transgene SA, Illkirch-Graffenstaden, France),27 and GL-ONC 
(a  TK-,  hemagglutinin-,  F14.5L-  mutant  expressing  imaging 
transgenes; Genelux, San Diego, CA).28 This oncolytic virus class 
is therefore growing rapidly, and elucidating the selectivity mecha-
nisms that these agents exploit will be critical to maximize patient 
benefit and the design of future products in this class.
Despite  the  clinical  progress  with  JX-594,  the  mechanisms 
responsible for JX-594 cancer-selectivity remain poorly under-
stood. Kim et al. demonstrated that a TK-deleted vaccinia virus 
(Western Reserve strain) replicated to higher titers in MCF-7 and 
Panc-1 cancer cell lines compared to immortalized serum starved 
MRC-5 fibroblasts.20 This study did not assess JX-594 specifically, 
and it did not evaluate TK-deleted vaccinia in truly normal and 
non-immortalized cells. Likewise, the infected cancer cells were 
tumor cell lines that had been serially passaged in vitro for over a 
decade and therefore are unlikely to bear resemblance to cancer 
cells in patients. No selectivity mechanisms were evaluated. We 
therefore elected to determine whether JX-594 was truly cancer-
selective at a cellular level by studying diverse cancer and normal 
cell populations immediately after being obtained from patients. 
Once cancer-selectivity was demonstrated convincingly, we worked 
to elucidate cellular factors that were driving the cancer-selective 
replication and cytolysis of JX-594. We hypothesized that cellular 
TK levels would correlate with JX-594 activity since JX-594 has an 
inactivated TK gene; TK levels in cancer cells are reportedly con-
stitutively higher than in normal cells.29 We also hypothesized that 
JX-594 cancer-selectivity was driven by epiderma growth factor 
(EGF) receptor pathway activation; this pathway is known to be 
required for efficient vaccinia replication and carcinogenesis (acti-
vated in over 90% of all human solid tumors). Finally, we explored 
whether the disruption of the type-I IFN clearance mechanism in 
cancer cells was exploited by JX-594.
results
JX-594 efficiently kills tumor cells, including tumor 
initiating cells of various origins
The ED50 of JX-594 was assessed on a panel of cancer cell lines 
of different tissue origins (NCI60 cell line panel). Low concentra-
tions of JX-594 (<1 pfu/cell) were effective at reducing cell viabil-
ity of cell lines of various tissue origins, including colon (both Ras 
mutant  and  wild-type),  prostate,  breast,  ovarian,  lung,  kidney, 
skin, and brain cancer cells; leukemia cells were relatively resistant 
to JX-594 killing compared with other tumor types (Figure 1a).
Tumor initiating cells (TICs) of two different origins (lung and 
colon; representing large solid tumor populations clinically) were 
incubated with JX-594 or ultraviolet-inactivated JX-594 control. 
JX-594 showed a strong cytotoxic effect on all three TIC cell lines, 
with less than 10% residual cell viability after 5 days of infection 
(Figure 1b). Ultraviolet-inactivated JX-594 had no effect on cell 
killing.
JX-594 selectively replicates in primary human tumor 
biopsy tissue
In order to best model JX-594 infection of tumors in patients, 
surgically resected human primary tumor tissue material, and 
when possible, companion normal tissue from the same patient, 
was assayed for ex vivo sensitivity to JX-594 infection by moni-
toring expression of JX-594-driven β-galactosidase (β-gal) or 
green fluorescent protein (GFP), and for viral replication in a 
subset of samples. A total of 29 patients had tumor tissue samples 
obtained from surgical resection specimens acutely. In addition, 
8 of these patients also had adjacent normal tissue obtained and 
assayed from the same surgical specimen. Cancer types included 
colorectal (n = 4), ovarian (n = 6), endometrial (n = 7), glioblas-
toma (n = 5), and non-small cell lung (n = 4). Nine tumor samples 
had viral replication assayed (viral burst assay) 48 hours postin-
fection (Figure 1c). In total, 29 tumor samples, and 8 normal 
tissue samples were similarly assayed, and 17 out of 29 tumors 
(57%) showed JX-594-driven β-gal activity or GFP fluorescence 
following ex vivo infection (relative to uninfected tumor tissue) 
(Table 1). Ovarian tumor explants (n = 6) exhibited particular 
sensitivity to JX-594 ex vivo (83%). The eight normal tissues 
tested displayed either no apparent susceptibility to JX-594 (n = 7), 
or less sensitivity to JX-594 infection (n = 1) than companion 
tumor tissue (Note: invasion of tumor cells into normal tissue 
cannot be ruled out in the single normal tissue sample which 
exhibited  GFP  positivity)  (Table  1).  A  significant  difference 
between infectivity of tumor and normal tissue was observed   
(P = 0.04; Fisher’s exact test). As a more quantitative indication of 
the differential sensitivity of primary human tumor and normal 
tissues to JX-594 infection, and to confirm that reporter trans-
gene expression correlated with replication as predicted, a sub-
set of paired tumor and normal samples from four individuals Molecular Therapy  vol. 20 no. 4 apr. 2012  751
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were assayed for ex vivo viral amplification. These samples were 
selected on the basis that (i) the tumor specimen provided was 
scored as susceptible to JX-594–driven gene expression, and (ii) 
the responsive tumor specimens were accompanied by a normal 
organ tissue biopsy sample. Virus amplification in the tumor tis-
sue ~100- to 3,000-fold higher than in the companion normal 
tissue (Figure 2a).
Peripheral blood mononuclear cells are resistant to 
JX-594 replication
In its clinical application as an oncolytic viral therapy for can-
cer, JX-594 can be found in circulation of patients shortly after 
intravenous or intratumoral administration, and at later times 
post-treatment as in vivo replication occurs.22 As blood cells will 
come into contact with JX-594, either through direct intravenous 
delivery or during secondary spread following in vivo replication, 
it is important to determine whether blood cells become infected 
by  JX-594.  Peripheral  blood  mononuclear  cells  (PBMC)  were 
isolated from naive whole blood, and inoculated with JX-594, 
and virus-driven β-gal activity was quantified by flow cytometry. 
As a comparison, U2OS human osteosarcoma cells were simi-
larly infected and assayed. PBMC displayed between 0.02 and 
0.73% β-gal expressing cells over a 24–72 hours period follow-
ing infection with JX-594 at multiplicity of infection (MOI) of 1   
(Figure 2b). To address any concern that activation of PBMC 
may enhance their susceptibility to viral infection, donor PBMC 
(collected as described) were activated with phytohemagglutinin 
(PHA) before infection with JX-594. JX-594-driven β-gal expres-
sion in PBMC stimulated with PHA (5 μg/ml) occurred in only 
0.05–9.63% over the same timeframe (Figure 2b). However, back-
ground β-gal expression in uninfected PHA-stimulated PBMC 
ranged from 0.12 to 3.23% in this same timeframe. In contrast, 
U2OS human osteosarcoma cells infected with JX-594 at MOI 
of 1 showed 28.11% of cells expressing virus-driven β-gal activ-
ity at 24 hours postinfection, increasing to 43.35% at 48 hours, 
and peaking at 98.15% by 72 h postinfection (Figure 2b). PBMC 
were therefore highly refractory to JX-594 viral gene expression, 
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Figure 1  JX-594 replicates and induces cytolysis in a broad spectrum of cancer cell types, including cell lines, tumor initiating cells, and pri-
mary human tumor tissue. (a) JX-594 ED50 (pfu/cell) on human cell lines in the NCI cell line panel upon JX-594 infection at multiple multiplicities of 
infection (MOI) 72 hours postinfection (n = 3). Ras mutational status for colorectal cancer cell lines is indicated. Error bars = SD. (b) Percent viability 
(compared to untreated control) over time of three tumor initiating cell lines (lung or colon) following infection with JX-594 or UV-inactivated JX-594 
control at an MOI of 3 (n =3). Error bars = SD. (c) Human tumor biopsy material was sliced into 5 × 5 × 5 mm segments and infected with 5 × 106 pfu 
JX-594 suspended in 100 μl α-MEM serum-free medium ex vivo. Samples were homogenized and infectious virus quantitated 48 hours postinfection. 
MEM, minimum essential medium; NCI, National Cancer Institute; NSCLC, non-small-cell lung cancer; UV, ultraviolet.
table 1  JX-594 preferentially infects and expressed its transgene in 
primary human tumor biopsy tissue ex vivo
cancer type tumor tissue normal tissue
Brain 2 of 5 N/A
Lung 1 of 4 0 of 3
Colon/rectal 2 of 4 1 of 3
Ovarian 5 of 6 N/A
Cervical 0 of 1 N/A
Vulvar 1 of 1 N/A
Endometrial 6 of 7 0 of 1
Renal 0 of 1 0 of 1
Total infection rate 17 of 29 (57%) 1 of 8 (13%)
Abbreviations: N/A, not applicable.
Human tumor biopsy material, and when possible accompanying normal organ 
tissue samples, were sliced into 5 × 5 × 5 mm segments and infected with 5 × 106 
pfu JX-594 ex vivo. JX-594 infection was monitored by fluorescence microscopy 
48 hours postinfection. Samples were scored as susceptible to JX-594 infection if 
fluorescence was greater in the infected tissue relative to the uninfected relevant 
control; samples were considered resistant if there was no increase in green 
fluorescence in infected tissue relative to uninfected control tissue. In total 29 
tumor samples and 8 normal tissue samples were assayed, and the results are 
reported in this table.752  www.moleculartherapy.org  vol. 20 no. 4 apr. 2012     
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relative to the human cancer cell line U2OS, at a high MOI over 
72 hours of infection.
In duplicate samples, PBMC and U2OS infected with JX-594 
underwent three freeze-thaw cycles before titering on U2OS cells 
to assess virus production (Figure 2c). JX-594 did not replicate 
significantly in JX-594-infected PBMC, even after PHA stimula-
tion. In contrast, U2OS cells produced ~100-fold higher pfu when 
compared to PBMC at 24 hours postinfection, and ~1,000-fold 
more by 48–72 hours.
selective replication of JX-594-luc+/β-gal− in tumors 
in vivo
As an in vivo demonstration of the tumor-selectivity of JX-594 
replication, CD1 nude mice bearing subcutaneous SW620 human 
colon carcinoma xenograft tumors were treated with JX-594-firefly 
luciferase (luc)+/β-gal− via the intravenous route followed by bio-
luminescence imaging by in vivo imaging system (IVIS; Xenogen, 
Hopkinton, MA). Bioluminescence imaging has previously been 
shown to correlate with vaccinia titer.30 As shown in Figure 3a, 
luminescence is highly tumor-selective (days 3 and 6). As a more 
quantitative measure of longer term replication of intravenously 
delivered virus in vivo, mice bearing subcutaneous SW620 tumors 
were euthanized and multiple tissues collected 7 days postinfu-
sion for viral titering (pfu/g tissue). Infectious JX-594-luc+/β-gal− 
pfu were ~5 or more logs higher in tumor tissues compared with 
any other organ tissue tested, including brain, heart, kidneys, liver, 
lungs, ovaries, and spleen (Figure 3b). Concomitant treatment 
of mice with universal IFN-α resulted in reduced JX-594-luc+/   
β-gal− output in normal tissues while not affecting JX-594-luc+/
β-gal− titers recovered from tumors (Figure 3b).
JX-594-luc+/β-gal− selectivity was also assessed in a transgenic 
mouse model of ovarian cancer; in this model the transforming 
region of SV40 is driven by the Mullerian inhibitory substance 
type II receptor gene promoter resulting in bilateral ovarian car-
cinomas.31 Mice were treated with 108 pfu JX-594-luc+/β-gal− via 
the intraperitoneal route and assessed by IVIS for biolumines-
cence imaging on day 5 (Figure 3c); luciferase expression was 
only observed at the site of the cancerous tissue in the ovaries.
JX-594 replication correlates with cellular tK levels
JX-594 is a Wyeth strain vaccinia virus with a disruption and inac-
tivation of the viral TK gene; thus infection should be dependent 
on the presence of sufficient cellular TK. Cancer cells are known 
to have high constitutive TK concentrations compared to normal 
cells. To assess the dependence of JX-594 replication on cellular 
TK levels, HeLa cells with high levels of endogenous TK were 
infected with a lentivirus expressing a TK-directed short hairpin 
RNA (shRNA). Reduction in endogenous TK levels was confirmed 
(Figure 4a). Both JX-594 and wild-type Wyeth control replica-
tion was subsequently assayed in the HeLa cell line as well as the 
TK-knockdown clone. JX-594 burst size was attenuated in cells 
with reduced TK levels when compared to control cells; no effect 
on wild-type Wyeth virus was observed in the TK-knockdown 
clone  (Figure 4b).  Decreased  JX-594  output  upon  TK  knock-
down was confirmed using two additional TK-knockdown clones 
(Supplementary Figure S1).
JX-594-GFP+/β-gal− replication is dependent on 
eGFr/ras/MAPK pathway signaling
Since wild-type vaccinia virus has been shown to be dependent on 
EGFR signaling,32 we sought to investigate whether JX-594 rep-
lication  is  dependent  on  EGFR/Ras/MAPK  (mitogen-activated 
protein kinase) signaling. An inhibitor specific for extracellular 
signal-regulated kinase (U0126) was used to interrogate JX-594 
dependence on this pathway at concentrations that did not affect 
cell viability (data not shown). Incubation of two human colorec-
tal cancer cell lines (SW620 and HCT116) with U0126 inhibited 
JX-594-GFP+/β-gal− replication (Figure 5).
selective inhibition of in vitro JX-594-GFP+/β-gal− 
replication in normal human fibroblasts but not in 
cancer cells
Previous reports have demonstrated that TK-deleted vaccinia virus 
preferentially infects cancer cells as compared to serum-starved 
MRC-5 cells (secondary human lung fibroblasts).20 In addition, 
it is known that cancers often have a defective IFN response.6 To 
demonstrate cancer-selective replication of JX-594 with greater 
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Figure 2  JX-594 preferentially infects tumor tissue, while sparing normal tissue. (a) Human tumor biopsy material, and when possible accom-
panying adjacent normal organ tissue samples, were sliced into 5 × 5 × 5 mm segments and infected with 5 × 106 pfu JX-594 or JX-594-GFP+/β-gal− 
ex vivo. When possible, paired normal and tumor tissue samples wherein the tumor displayed virus-driven fluorescent reporter expression, were 
homogenized and titered to quantify infectious virus recovered from the specimen 48 hours postinfection. The ratio of JX-594-GFP+/β-gal− in tumor 
tissue versus the corresponding normal tissue is plotted. (b) Donor PBMC from a healthy volunteer were cultured for 24 hours in the presence or 
absence of PHA (5 μg/ml) before infection with JX-594. PBMC or U2OS cell cultures were then inoculated with JX-594 at an MOI = 1 pfu/cell and after 
24, 48, or 72 hours. β-gal activity was detected by flow cytometry using ImaGene Green LacZ detection kit (n =1). (c) JX-594 output from duplicate 
culture/infection conditions as measured by plaque assay (n = 1). β-gal, β-galactosidase; GFP, green fluorescent protein; MOI, multiplicity of infection; 
PBMC, peripheral blood mononuclear cells; PHA, phytohemagglutinin.Molecular Therapy  vol. 20 no. 4 apr. 2012  753
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stringency, infection experiments on GM38 cells (human fibro-
blasts)  and  SW620  cells  were  conducted  in  the  presence  and 
absence of exogenously supplied IFN-α, a downstream mediator of 
IFN-β.7 Cells were infected with JX-594-GFP+/β-gal− in vitro, in 
the presence and absence of exogenous IFN-α, and the progression 
of JX-594-GFP+/β-gal− infection was monitored over 48 hours by 
fluorescence microscopy. JX-594-GFP+/β-gal− transgene expres-
sion in the presence of IFN-α was markedly higher in SW620 cells 
versus normal human fibroblasts (Figure 6a). These results are in 
accordance with decreased JX-594-luc+/β-gal− output detected in 
normal tissues following treatment of tumor-bearing mice with 
JX-594-luc+/β-gal− and universal IFN-α (Figure 3b).
UACC257 melanoma cells were infected with JX-594-GFP+/
β-gal− in the presence of increasing concentrations of IFN-α and 
evaluated for viability 72 hours later. In the absence of IFN-α 
UACC257 cells were efficiently killed with an EC50 of less than 
5 × 102 pfu when compared to the EC50 on GM38 normal fibro-
blasts (2.7 × 103 pfu). However, in the presence of low concen-
trations of IFN-α (250 IU), the EC50 of JX-594-GFP+/β-gal− on 
GM38 cells shifted to 1.7 × 104 pfu while UACC257 cells were not 
protected with IFN-α treatment (even at a high dose of 1,000 IU) 
(Figure 6b).
dIscussIon
We  describe  here  multiple  distinct  cancer-selectivity  mecha-
nisms,  both  inherent  and  engineered,  for  the  oncolytic  virus 
JX-594. To our knowledge, this is the first such description in 
the literature. To date, oncolytic viruses have been proposed to 
be cancer-selective on either an inherent or an engineered basis, 
with a single mechanism being proposed for the cancer-selec-
tivity of each virus. In this study we demonstrate three mecha-
nisms  contributing  to  the  tumor-selectivity  of  JX-594,  a  TK 
gene-inactivated Wyeth vaccinia virus expressing GM-CSF and 
lac-Z transgenes. Two mechanisms that drive JX-594 replication 
are inherent to cancer cell biology: (i) activation of the EGFR/
Ras/MAPK signal transduction pathway and (ii) inactivation of 
the type-I IFN response pathway. We predicted that these path-
ways would be critical since vaccinia virus is known to manipu-
late these cellular pathways for (i) its replication and spread and 
(ii) to avoid IFN-mediated clearance; this was confirmed experi-
mentally as published here. In fact, vaccinia secretes viral pro-
teins from the infected cell that activate the EGFR/Ras/MAPK 
pathway (vaccinia growth factor)33 or partially inactivate type-I 
IFNs (e.g., B18R),34 and inhibitors of EGFR were demonstrated 
to block vaccinia replication.32,35 A third mechanism that drives 
selective replication relates to the engineered inactivation of the 
TK gene in JX-594 and the resulting reliance on high cellular TK 
concentrations for replication; TK activity is constitutively high 
in many cancer cells.29 Given prior data that a TK-inactivated 
vaccinia virus is attenuated in normal cells,36 we theorized that 
cellular TK levels would correlate with JX-594 replication. Since 
TK is an E2F-responsive gene, TK levels in cancer cells are gener-
ally higher and constitutive compared to normal cells (includ-
ing cycling normal cells). Therefore, three distinct mechanisms 
for the cancer-selectivity of JX-594 are reported herein, and both 
inherent and engineered mechanisms contribute. Nevertheless, it 
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Figure 3  In vivo biodistribution of JX-594-luc+/β-gal− infection and replication following intravenous administration. (a) Athymic nude mice 
with established subcutaneous SW620 human colon carcinoma tumors were treated intravenously via the tail vein with 107 pfu JX-594-luc+/β-gal−. 
Three and 6 days postinfection, luminescence was assessed emanating from the tumor and normal tissue with IVIS system. (b) Athymic nude mice 
bearing subcutaneous SW620 tumors treated with intravenous JX-594-luc+/β-gal− at a dose of 1 × 107 pfu in a, as well as mice treated with JX-594-
luc+/β-gal− and universal IFN-α were sacrificed 7 days following JX-594-luc+/β-gal− treatment. Organs were collected and the presence of virus was 
quantified by plaque assay in U2OS cells (n = 6 per group). Error bars = SD. (c) Female transgenic FVB/N mice with autochthonous ovarian tumors 
were treated with 1 × 108 pfu JX-594-luc+/β-gal− intraperitoneally, and 5 days later luminescence was assessed with a Xenogen 200 Series IVIS system. 
β-gal, β-galactosidase; IFN, interferon; IVIS, in vivo imaging system; luc, firefly luciferase; MOI, multiplicity of infection; shRNA, short hairpin RNA; TK, 
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is highly likely that additional cellular mediators are involved and 
will be discovered.
JX-594 demonstrated broad spectrum efficacy against diverse 
solid tumor types, both in cell lines and in ex vivo assays with pri-
mary human tissue explants. Of note, lung and colorectal TICs 
were also sensitive to JX-594-mediated destruction. This is of sig-
nificance as TICs are known to be generally resistant to currently 
approved chemotherapies.37 Since JX-594 is able to target can-
cer cells with common genetic signatures, and because vaccinia 
uptake into cells is via a mechanism that is ubiquitous (apoptotic 
bleb  mimicry),18  broad  spectrum  activity  was  predicted.  The 
EGFR/Ras pathway, for example, is activated in the vast majority 
of human carcinomas (>90%), either by activation of the receptor 
or downstream signaling molecules (e.g., Ras, Raf).38–41 It remains 
to  be  determined  which  downstream  mediators  in  the  EGFR/
Ras pathway drive JX-594 replication, spread, and cytolysis most 
potently. Since JX-594 is activated for replication and spread by 
EGFR pathway signaling, regardless of which component in the 
pathway is activated, JX-594 can potentially be more broadly effec-
tive than EGFR inhibitors (e.g., cetuximab, erlotinib). Tumors can 
develop resistance to these inhibitors by activating downstream 
signaling molecules (e.g., Ras) or parallel, redundant pathways.42,43 
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Figure 4  JX-594 replication is attenuated in cancer cells depleted 
of  cellular  thymidine  kinase  (tK).  (a)  Western  blotting  confirming 
knockdown  of  endogenous  TK  in  HeLa  cells  performed  by  retroviral 
transduction using shRNA against TK, or a control shRNA. (b) JX-594 
and wild-type Wyeth control replication in HeLa cells or TK-knockdown 
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Figure 5  JX-594-GFP+/β-gal− replication is attenuated in the pres-
ence of an erk inhibitor. Two human colon carcinoma cell lines (SW620 
and HCT116) were infected with JX-594-GFP+/β-gal− at an MOI of 0.1 for 
50 hours in the presence or absence of the Erk inhibitor U0126. JX-594-
GFP+/β-gal− output from triplicate culture/infection conditions was mea-
sured by plaque assay (n = 3). Error bars = SD. β-gal, β-galactosidase; 
DMSO,  dimethyl  sulfoxide;  Erk,  extracellular  signal-regulated  kinase; 
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Figure 6  JX-594-GFP+/β-gal− replication is attenuated in the pres-
ence  of  interferon  on  normal  cells,  but  not  on  cancer  cells.  (a) 
SW620 human colon carcinoma cells (interferon-resistant) and GM38 
normal  human  fibroblasts  (interferon-sensitive)  were  inoculated  with 
JX-594-GFP+/β-gal− (MOI 0.001–1) in the presence or absence of 200 IU/
ml exogenous IFN-α and transgene expression (GFP) was monitored 48 
hours postinfection using a Zeiss Axiovision microscope and Axiovision 
acquisition and image storage software. (b) GM38 normal human fibro-
blasts and UACC257 human melanoma cells (interferon-resistant) were 
seeded (3 × 104 cells per well) in the presence or absence of varying 
concentrations of IFN-α and infected with JX-594-GFP+/β-gal− at vari-
ous MOIs, and 72 hours later cell viability was assessed by CellTiter Blue 
assay (n = 4). β-gal, β-galactosidase; GFP, green fluorescent protein; IFN, 
interferon; MOI, multiplicity of infection.
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JX-594 was active against EGFR inhibitor-resistant tumors both 
in vitro and in patients. The exact prevalence of IFN resistance 
mechanisms  and  elevated  TK  levels,  two  other  predictors  of 
JX-594 sensitivity, for specific cancer patient populations remains 
to  be  established.  The  cellular  uptake  of  vaccinia  by  receptor- 
independent mechanisms may result in broader spectrum activity 
than is reported with other oncolytic viruses. For example, Ad5 
uptake is coxsackievirus-adenovirus receptor (CAR)-dependent, 
thus resulting in poor uptake and efficacy against tumors with low 
CAR expression.44
Significant questions still remain with regard to the cancer-
targeting selectivity of JX-594. In clinical trials of intratumoral 
and/or intravenous administration of JX-594, cancer-selectivity 
and safety have been established. Transient flu-like symptoms have 
been the predominant toxicity, while organ tissue toxicities have 
not been reproducibly demonstrated to date.19,22,23 Nevertheless, 
it is theoretically possible that certain normal cell populations 
within the body could be susceptible to toxicity. Highly prolif-
erative cells in the bone marrow do not appear to be susceptible 
since intravenous therapy in patients does not result in reproduc-
ible durable cytopenias23; interestingly, leukemia cells and prolif-
erating normal PBMC were also highly resistant. Although gut 
crypt epithelial cells are highly proliferative, gut toxicity was not 
described in either GLP toxicology studies nor in >100 patients 
treated to date.20,22,23 It is possible that these normal proliferating 
cells remain resistant due to the fact that the IFN resistance mech-
anism is intact in these tissues, in contrast to tumors. The toxicity 
of JX-594 and related viruses at sites of wound healing remains to 
be determined. To date, the agent has been used without toxic-
ity in patients receiving tumor biopsies or percutaneous needle 
insertions.22,23 Finally, the roles of vaccinia proteins that interact 
with the EGFR (e.g., VGF), nucleotide synthesis (e.g. ribonucle-
otide reductase) or type-I IFNs (e.g. B18R) remain to be eluci-
dated in human tumors. Safety may be enhanced by the multiple 
cancer-selectivity mechanisms involved, rather than reliance on a 
single mechanism for cancer targeting.
In this publication we describe the cancer-selectivity of an 
oncolytic virus in a number of highly relevant in vitro and in vivo 
models. These methods have major implications for the field since 
they are likely more relevant to human cancer patient safety with 
oncolytic  viruses  than  previously  published  methods.  To  date, 
most reported selectivity data has been derived from “normal” 
cell lines such as fibroblasts that do not reflect normal tissues in 
patients. First, these cells are not epithelial, and second they are 
immortalized and therefore not normal. In addition, the contri-
bution of endogenous IFN on virus inhibition is often ignored in 
these assessments. Our goal was to assess potential selectivity and 
safety in a variety of normal tissues, including those most likely 
to be exposed after intravenous administration: vascular endothe-
lial cells and blood cells. Instead of using immortalized cell lines, 
we tested primary cells directly obtained from humans without 
extensive serial passaging. This assay could form the basis for a 
predictive test that which is more likely to be more clinically use-
ful than assays that assess a single genetic feature of a target tumor. 
Although these methods represent a major advance for the field, 
our methods do still have some limitations. First, it is extremely 
difficult to assess any immune-mediated toxicities that could occur 
in vivo. Second, the assessment of JX-594 selectivity in mice suffers 
from the fact that viral replication is markedly higher in human 
versus murine tissues; therefore, the tumor-selectivity shown after 
intravenous infusions may be due not only to differences in cancer 
versus normal cells, but also due to species differences. Orthotopic 
tumor implantation may also be more reflective of the clinical sit-
uation. Rabbit tumor models may be superior since normal rabbit 
tissues appear to be more susceptible to wild-type Wyeth vaccinia 
(parental strain for JX-594) than mouse tissues.20 Primate models 
may be more relevant for safety assessments, but tumor-targeting 
cannot be simultaneously assessed.
These findings have significant implications for future devel-
opment in the field. Given the multiple levels of safety and selec-
tivity we describe with JX-594, it is likely that many of these same 
mechanisms are important for other oncolytic viruses. These find-
ings may help to explain controversies in the literature surround-
ing the predictive utility of single genetic markers for infection 
and replication. Given the complexity of cancer genetics and virus 
replication, it is highly unlikely that a single genetic feature, or 
even activation of an entire signal transduction pathway, will be 
completely predictive on its own for cell sensitivity to an oncolytic 
virus. The excellent safety profile described for JX-594 and other 
oncolytic viruses entering the clinic to date5 may be a result of 
this multi-mechanistic selectivity. Due to selective amplification 
in tumors (e.g., several logs increase over a 1 week period) with 
simultaneous clearance from normal tissues, targeted oncolytic 
viruses have the potential for a much larger therapeutic index 
than other cancer therapeutics such as chemotherapy. These find-
ings also have implications for combination therapy with JX-594; 
inhibitors of the EGFR signaling pathway, for example, should be 
avoided for simultaneous treatment and should be used sequen-
tially. Finally, the high degree of cancer-selectivity demonstrated 
with JX-594 suggests that safe and systemically delivered multi-
mechanistic poxvirus products are possible. By engineering these 
agents with multiple transgenes encoding for therapeutic proteins, 
high-level cancer specific expression of multiple therapeutic pro-
teins could be achieved in solid tumors. Multiple mechanisms-
of-action can therefore be designed and engineered into these 
products. This may represent a breakthrough for the in vivo sys-
temic delivery and efficacy of cancer biologics in general.
MAterIAls And Methods
Viruses. Vaccinia virus JX-594 was previously described.19,20 Serial deriva-
tives of JX-594 were used in the laboratory in order to easily assess JX-594 
replication.  These  include  JX-594-GFP+/β-gal  and  JX-594-luc+/β-gal 
which express GFP and luc, respectively, instead of β-gal under the syn-
thetic early/late promoter pSE/L in the vaccinia TK gene locus. The vaccinia 
virus Wyeth strain was obtained from American Type Culture Collection 
(distributed  by  Cedarlane  Laboratories,  Burlington,  Ontario,  Canada). 
JX-594 was propagated in HeLa cells; all other viruses were propagated 
in U2OS cells.
Cell lines. U2OS (human osteosarcoma), SW620, HCT116 (human col-
orectal cancer), and UACC257 cells (human melanoma) were obtained 
from the NCI/NIH (Bethesda, MD) and maintained in Dulbecco’s modi-
fied Eagle medium (DMEM) + 10% fetal bovine serum (FBS) (HyClone, 
Hudson,  NH).  GM38  (human  skin  fibroblasts)  were  obtained  from   
Dr Bruce McKay (Ottawa Hospital Research Institute, Ottawa, Ontario, 
Canada) and were propagated in DMEM + 10% FBS. Susceptibility of the 756  www.moleculartherapy.org  vol. 20 no. 4 apr. 2012     
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NCI tumor cell line panel to JX-594 was screened by the In Vitro Cell Line 
Screening  Program  (DTP;  SAIC/NCI-Frederick,  Frederick,  MD).  Sixty 
different human tumor cell lines representing leukemia, melanoma, and 
cancers of the lung, colon, brain, ovary, breast, prostate, and kidney were 
incubated with serially diluted JX-594 virus inocula, in the range of 2–2 
× 105 pfu/200 μl/well. Cell death was determined after 72 hours by 2,3-
bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT) assay as described.45 ED50 values are reported and represent the 
initial virus MOI to achieve 50% cell killing compared to untreated control 
cells at 72 hours postinoculation.
Infection of TICs with JX-594. TIC cultures (TriStar Technology Group, 
Rockville,  MD)  were  established  and  propagated  under  spherogenic 
conditions as described.46 Cells were cultured for 20–30 days in serum-
free medium containing EGF (tebu-bio, Le Perray en Yvelines, France) 
and basic fibroblast growth factor (tebu-bio) before plating for the cyto-
toxicity assay. The cytotoxicity of the JX-594 virus was measured by the 
CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI) 
in a 96-well microplate format. TIC cultures, two from each of colorectal 
cancer47 and non-small-cell lung cancer,46 were supplemented with a single 
dose of oncolytic virus or control virus (MOI = 3) and kept in culture for 
24, 48, 72, 96, and 120 hours, respectively. A single cell density, determined 
to be in the linear range of the assay at all timepoints, was chosen and 
three replicates for each experimental point were included. At the end of 
the incubation, cell viability was determined by adding the CellTiter-Glo 
Reagent (Promega), and measuring the luminescent signal. JX-594 cyto-
toxicity was evaluated in comparison to its inactivated control. Suitable cell 
aliquots were withdrawn from master TIC cultures, collected by low-speed 
centrifugation (900 rpm for 5 minutes at 20 °C), enzymatically dissociated 
in 250 μl of Accumax Reagent (Sigma-Aldrich, Oakville, Ontario, Canada) 
for  5–10  minutes  at  37 °C,  and  counted.  By  low-speed  centrifugation 
(900 rpm for 5 minutes at 20 °C), 2.0 × 105 cells of each master cell culture 
were collected and enzymatically dissociated as above, then diluted in 5 ml 
of TIC basal medium for washing. Cell pellets were collected by low-speed 
centrifugation (900 rpm for 5 minutes at 20 °C), and resuspended again in 
5 ml of TIC basal medium plus growth factors at a final concentration of 
40,000 cells/ml. Fifty microliters of cell suspension were added to each well 
of five 96-well black microplates with clear, flat bottom. A single cell den-
sity of 2,000 cells was chosen to be within the linear range of the assay at 
all timepoints for all TIC lines. Cells were seeded in a sufficient number 
of wells for performing two single-dose infections, with JX-594 virus and 
ultraviolet-inactivated JX-594 virus, at five time points (24, 48, 72, 96, and 
120 hours), including three replicates for each experimental point. In addi-
tion, 1:2 serial cell dilutions from 2,000 to 125 cells/well were also plated 
in triplicate for each timepoint to obtain internal reference cell titration 
curves. Control wells containing medium without cells were used to obtain 
background assay values. After plating, cells were incubated for 2 hours at 
37 °C, before the addition of 50 μl/well of a viral suspension containing 6,000 
pfu (to infect cells at an MOI of 3). Initially, 50 μl of viral stocks (108 pfu/ml) 
were diluted 1:10 in 500 μl to obtain a 107 pfu/ml concentration; a second 
dilution 1:10 was prepared to obtain 500 μl of 106 pfu/ml concentration. 
The whole volume (500 μl) was further diluted by addition of 3.65 ml of 
culture medium to reach the final concentration of 1.2 × 105 pfu/ml. All 
dilutions were made in TIC basal medium plus GFs. Then cell cultures 
were incubated at 37 °C in the presence of the viral agents for 24, 48, 72, 96, 
or 120 hours. At the end of each incubation time the number of viable cells 
was determined using the CellTiter-Glo Luminescent Cell Viability Assay 
(Promega), essentially by following the manufacturer’s recommendations. 
Luminescence was recorded using a Perkin Elmer Wallac 1450 MicroBeta 
TriLux detector (PerkinElmer, Waltham, MA).
Human tumor biopsy infection with JX-594 ex vivo. Surgical biopsy mate-
rial was obtained from patients at the Ottawa Hospital General Campus 
undergoing surgery to biopsy or remove solid organ malignancies under 
Protocol 2004266-01H. A total of 29 tumor samples, of which 8 were 
accompanied by normal tissue from the affected organ, were assayed for 
their sensitivity to JX-594 or JX-594-GFP+/β-gal−. Informed consent was 
obtained from all patients before surgery. Samples were received in cell 
culture medium at room temperature from the Ottawa Hospital General 
Campus and were processed within 2–16 hours. Small slices (~5 × 5 × 
5 mm) of specimens were prepared in a sterile biosafety cabinet using a 
sterile surgical blade and forceps. A single tissue portion was placed into 
one well of a 24-well sterile tissue culture plate for infection. Samples were 
inoculated with 5 × 106 pfu JX-594 or JX-594-GFP+/β-gal− in 100 μl of 
α-minimum essential medium (α-MEM) serum-free medium. Virus was 
allowed to adsorb for 2 hours at 37 °C, at which time 1.9 ml of α-MEM sup-
plemented with 10% FBS was added. Infected tissue specimens were incu-
bated in a humidified incubator at 37 °C for 24 or 48 hours before imaging 
JX-594-driven β-gal activity or GFP. Briefly, endogenous β-gal activity in 
explant tissues was blocked by incubation with 300 μmol/l chloroquine 
for 2 hours at 37 °C. Following this blocking step, chloroquine-containing 
medium was aspirated and tissues were incubated with 500 μl of a 33 μmol/l 
working stock of C12FDG substrate for 30 minutes at 37 °C before adding 
phenyl-ethyl β-D-thiogalactopyranoside (PETG) to a final concentration 
of 1 mmol/l to stop the reaction. Explants were photographed under a 
Leica MZ FLIII fluorescent dissecting microscope (at ×2–4 magnification; 
Leica, Wetzlar, Germany) and images were stored using Adobe Photoshop 
version 7.0.
The determination of positive or negative responses in terms of tissue 
sensitivity to infection with JX-594 or JX-594-GFP+/β-gal− is qualitative. 
Tissue samples were considered to be susceptible to JX-594 infection if 
green fluorescence following C12FDG staining was greater in the infected 
tissue compared to the background fluorescence in the uninfected relevant 
control.  Tumor  tissue  samples  were  scored  as  resistant  if  there  was  no 
increase  in  green  fluorescence  in  infected  tissue  relative  to  uninfected 
control tissue. Normal tissue samples were scored as resistant if there was no 
increase in green fluorescence in infected tissue relative to uninfected tissue 
or if the normal tissue was less susceptible than companion tumor tissue.
When  possible,  paired  normal  and  tumor  tissue  samples  were 
homogenized and titered by plaque assay to quantify infectious virus 
recovered from the specimen 48 hours postinfection.
Plaque assay for JX-594 quantification in cells infected in vitro. Cells 
infected with JX-594, JX-594-GFP+/β-gal− or JX-594-luc+/β-gal− in vitro 
underwent three freeze-thaw cycles before plating. Tissue samples infected 
with virus were thawed once, and homogenized before plating. Samples 
were serially diluted in serum-free α-MEM tissue culture medium and 
1 ml of each dilution was plated onto a monolayer of U2OS cells, estab-
lished by plating 106 cells/well of a 6-well plate the day before initiating 
the plaque assay. After 2 hours of incubation at 37 °C, a semi-solid overlay 
of carboxymethylcellulose in α-MEM supplemented with 10% FBS was 
applied. Plates were incubated for an additional 48 hours, at which time 
plaques were fixed and stained with 0.1% Crystal violet in 80% methanol.
Ex vivo PBMC infection. Blood was drawn from healthy volunteers into 
heparinized  vacutainer  tubes  and  diluted  1:3  in  phosphate-buffered 
saline (PBS). Diluted blood was overlayed onto 5 ml Ficoll-Paque Plus 
(Amersham-Pharmacia, Uppsala, Sweden) and the buffy coat layer con-
taining PBMC was isolated following centrifugation at 400g for 25 minutes 
at room temperature. PBMC were washed twice in PBS and resuspended 
to 106 cells in 1 ml of DMEM + 10% FBS. Cells were cultured for 24 hours 
in the presence or absence of PHA (5 μg/ml) before infection with JX-594. 
Cultures of resting or stimulated PBMC were inoculated with JX-594 at 
MOI of 1 pfu/cell for 2 hours at 37 °C. Cultures were supplemented with 
DMEM containing 10% FBS and cultured for an additional 24–72 hours 
before flow cytometric analysis to detect β-gal activity, using the ImaGene 
Green lacZ Gene Expression Kit (Molecular Probes, Eugene, OR) according 
to manufacturers’ instructions. Briefly, cells were incubated in 300 μmol/l Molecular Therapy  vol. 20 no. 4 apr. 2012  757
© The American Society of Gene & Cell Therapy
JX-594 Selectively Destroys Cancer Cells
chloroquine reagent for 2 hours at 37 °C and washed in PBS. Cells were 
resuspended in 1 ml of 33 μmol/l C12FDG substrate reagent and incubated 
at 37 °C for 30 minutes before stopping the reaction with 1 mmol/l PETG. 
Infection of cells and cell viability were quantitated by flow cytometric 
analysis using a Beckman-Coulter Epics XL flow cytometer (Beckman 
Coulter, Mississauga, Ontario, Canada) and Expo32 acquisition software. 
Detectors for C12FDG and propidium iodide were FL1 and FL2, respec-
tively. U2OS cells were similarly infected in parallel, albeit without addi-
tional PHA stimulation. Duplicates of all culture/infection conditions were 
prepared and were frozen at −80 °C until thawing to assay JX-594 viral out-
put by plaque assay.
Murine tumor models. Athymic nude mice (Charles River, Wilmington, 
MA)  were  implanted  with  subcutaneous  human  SW620  colon  cancer 
xenografts by injecting 5 × 106 SW620 cells in 200 μl PBS, which were 
allowed to grow for 14 days. At this time, all mice were treated with 107 pfu 
of JX-594-luc+/β-gal−, by the intravenous route (tail vein). Mice receiv-
ing universal IFN-α (PBL Interferon Source, Piscataway, NJ) were given an 
intraperitoneal injection of 5 × 104 IU at the time of JX-594 infusion.
Thirteen-week-old female FVB/N mice expressing the transforming 
region  of  SV40  driven  by  the  Mullerian  inhibitory  substance  type  II 
receptor gene promoter31 were treated with a single intraperitoneal dose 
of JX-594-luc+/β-gal− (1 × 108 pfu).
All experiments were conducted with the approval of the University 
of Ottawa Animal Care and Veterinary Service.
Bioluminescent imaging of JX-594 replication. Mice were injected with 
d-luciferin (Molecular Imaging Products Company, Ann Arbor, MI; 200 μl 
intraperitoneally at 10 mg/ml in PBS) to image JX-594-driven luc expres-
sion. Mice were anesthetized under 3% isofluorane and imaged with the 
200 Series in vivo Imaging System (Xenogen). Data acquisition and analy-
sis was performed using Living Image v2.5 software (Xenogen). In vivo 
imaging was performed at the indicated timepoints postinfection.
In vivo biodistribution. Nude mice bearing SW620 human colon cancer 
xenograft  subcutaneous  tumors  were  injected  with  107  pfu  JX-594  IV. 
Seven days post-injection, mice were euthanized and tumors, liver, lungs, 
brain, spleen, heart, ovaries, and kidneys were collected and frozen at 
−80 °C. Subsequently, tissues were thawed, homogenized, and infectious 
virus titer was quantified by plaque assay as previously described.
TK knockdown. The Tk1 knockdown in HeLa cells was achieved through 
delivery of shRNA via lentiviral transduction. Short hairpins against human 
Tk1 were designed and cloned into a bicistronic lentivector pLVTHM 
which contains a GFP marker downstream of the shRNA sequence; trans-
duced cells stably expressing shRNA targeting Tk1 were selected based on 
expression of GFP. The stability of these Tk1 knockdown cells was moni-
tored using a Leica MZ FLIII fluorescent microscope and showed no signs 
of loss of the lentiviral vector. Parental or TK-knockdown HeLa cell clones 
were infected with JX-594 or Wyeth wild-type virus at MOI of 0.1 for a 
total of 48 hours before assessing virus replication.
Western  blotting.  Three  different  hairpins  were  found  to  successfully 
knockdown  Tk1  levels  in  HeLa  cells  using  western  blotting.  Mouse 
anti-human  Tk1  monoclonal  antibody  (clone  3B3.E11)  from  Novus 
Biologicals (Littleton, CO) was used at a 1:500 dilution, and the goat anti-
mouse IgG-HRP conjugated secondary antibody (Bio-Rad, Mississauga, 
Ontario, Canada) was used at a 1:1,000 dilution. The HRP-tagged second-
ary was detected by the enhanced chemiluminescence method using the 
SuperSignal West Pico Chemiluminescent substrate kit according to man-
ufacturer’s instructions (Pierce, Rockford, IL). The Tk1 level in the original 
HeLa (control) and the knockdown clones (A4, A5, D14) was quantified 
using the BioRad GS-800 Calibrated Densitometer (Bio-Rad, Hercules, 
CA) and QuantityOne software.
In  vitro  infection  with  extracellular  signal-regulated  kinase  inhibitor. 
Human colorectal cancer cell lines SW620 (provided by the NCI) and 
HCT116 (NCI) (106 cells/well) were pretreated for 2 hours with various 
concentrations of U0126 (Sigma, Oakville, Ontario, Canada). Cells were 
then inoculated with recombinant JX-594-GFP+/β-gal− at MOI of 0.1 pfu/
cell for 2 hours in serum-free medium. Cells were cultured in the presence 
of serum for an additional 48 hours, were harvested and virus replication 
was quantified by plaque assay and in duplicate cultures.
JX-594-GFP+/β-gal− imaging and cell viability assay in presence of IFN. 
SW620 human colon carcinoma cells (provided by the NCI), and GM38 
normal human fibroblasts (provided by Bruce McKay; OHRI, Ottawa, 
Ontario, Canada) were plated at 105 cells/well and cultured overnight in 
the presence or absence of 200 IU/ml human IFN-α (Schering Canada, 
Pointe-Claire, Quebec, Canada). Cells were then inoculated with JX-594-
GFP+/β-gal− at MOIs of 1.0, 0.1, 0.01, and 0.001 pfu/cell for 2 hours in 
serum-free medium. Cells were cultured in the presence of serum for an 
additional 48 hours, over which time cells were monitored for susceptibil-
ity to viral gene expression (GFP) by fluorescence microscopy.
GM38 normal human fibroblasts and UACC257 human melanoma 
cells were seeded (3 × 104 cells/well) in the presence or absence of varying 
concentrations  of  IFN-α  (Schering  Canada,  Pointe-Claire,  Quebec, 
Canada)  and  infected  with  JX-594  at  a  various  MOIs.  Seventy-two 
hours later, cell viability was assessed by CellTiter-Blue assay (Promega) 
according  to  manufacturer’s  instructions.  Fluorescence  was  read  on  a 
Fluoroskan (Thermo Scientific, Hudson, NH) at an excitation of 530 nm 
and emission of 590 nm.
Statistical  analyses.  All  statistical  analyses  were  performed  using  the 
GraphPad  Prism  5.0  software  (GraphPad  Software,  La  Jolla,  CA).  The 
unpaired t-test was used to assess differences in virus output in HeLa ver-
sus TK-knockdown cells. The Fisher’s exact test was used to assess differ-
ences in infectivity of tumor and normal tissue explants. GraphPad Prism 
software was also used to calculate the IC50 of JX-594 in normal and tumor 
cells in the presence and absence of IFN.
suPPleMentArY MAterIAl
Figure S1.  Reduced  TK  levels  affect  JX-594  output  in  multiple   
TK-knockdown clones.
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